ArticleJournal of clinical pharmacology2019

Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.

Whitney P Kirschbrown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.